Kidney-Friendly? early study checks hepatitis d drug in patients with impaired kidneys

NCT ID NCT05760300

Completed Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study looked at how the drug bulevirtide behaves in people with chronic hepatitis D who also have normal or impaired kidney function. Researchers measured drug levels in the blood, its effect on bile acids, and overall safety. The study enrolled 41 adults and gave them multiple doses of bulevirtide by injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bulevirtide (also known as Hepcludex or Myrcludex B)
What this could lead to: If successful, this study could help doctors understand how to safely use bulevirtide in hepatitis D patients with kidney issues.
What could go wrong: This is a very early (Phase 1) study with only 41 people. It focuses on drug levels and safety, not on curing hepatitis D. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS D INFECTION

Contacts and locations

Locations

Advanced Pharma CR, LLC

Miami, Florida, 33147, United States
Clinical Pharmacology of Miami, LLC

Miami, Florida, 33014, United States
Floridian Clinical Research, LLC

Miami Lakes, Florida, 33016, United States
Genesis Clinical Research, LLC

Tampa, Florida, 33603, United States
Global Clinical Professionals Research

St. Petersburg, Florida, 33705, United States
Massachusetts General Hospital - Renal Associates Clinic

Boston, Massachusetts, 02114, United States
Nucleus Network

Saint Paul, Minnesota, 55114, United States
Panax Clinical Research

Miami Lakes, Florida, 33014, United States
Velocity Clinical Research, New Smyrna Beach

Edgewater, Florida, 32132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.